Evidence map›Paper›PMID 40291670›Full record

ArticlebioRxiv : the preprint server for biology2025

FLASH radiotherapy spares lymphocytes in tumor-draining lymph nodes and increases infiltration of immune cells in tumors.

Francisco R Saenz, Brett Velasquez, Trey Waldrop, Edgardo Aguilar, Kathryn R Cox, Abagail Delahoussaye, Caddie Laberiano-Fernandez, Leticia Campos Clemente, Luke Connell, Nefetiti Mims and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Francisco R SaenzDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brett VelasquezDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Trey WaldropDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Edgardo AguilarDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kathryn R CoxDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abagail DelahoussayeDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Caddie Laberiano-FernandezDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leticia Campos ClementeDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luke ConnellDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nefetiti MimsDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Denae NeillDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Edwin R ParraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Karen Clise-DwyerDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emil SchülerDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael T SpiottoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NRSA Training CoreTL1TR003169 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHANDRA, JOYA, FROST, JEFFREY A. · 2019 to 2023
$3.7M
Research Supplements to Promote Diversity in Health-Related Research: Preclinical optimization of ultra-high dose rate (FLASH) radiotherapy parameters for translational relevanceR01CA266673 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SCHUELER, EMIL · 2022 to 2025
$3.5M
CTSA Predoctoral T32 at the University of Texas Health Science Center at HoustonT32TR004905 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Joya Chandra, Jeffrey A. Frost · 2024 to 2026
$811k
NCATS NIH HHS T32 TR004905NCATS NIH HHS TL1 TR003169NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA266673
6 · The paper itself

Abstract

Radiotherapy (RT) delivered at conventional dose rates (CONV) can both stimulate antitumor immune responses and inhibit these immune responses by depleting circulating lymphocytes. Given the observed normal tissue sparing associated with ultra-high dose rate (FLASH) RT, we hypothesized that FLASH RT may protect lymphocytes while increasing the immunogenicity of cancer cells. We irradiated cancer cell lines

Indexed as

adaptive immunityradiotherapytumor infiltrating lymphocytes

Identifiers

PMID40291670
PMCPMC12026895

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.